Navigation Links
Access Pharmaceuticals to Host Update Conference Call for Investors
Date:3/1/2011

DALLAS and NEW YORK, March 1, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, will host a conference call on Wednesday, March 23rd to update investors on its ongoing commercial and development strategy. Management will discuss the progress made within each of Access' programs, including an update on commercial launch activities and schedule for MuGard, the company's oral mucositis supportive care product; its Cobalamin CobOral and CobaCyte programs, as well as the advancement of both its Thiarabine Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center, and ProLindac phase 2 combination trial in recurrent ovarian cancer.

The conference call is scheduled to be held on Wednesday, March 23, 2011 at 11:00 am EST.  Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.  A replay of the call will be available starting on March 23, 2011 at 1:00 pm EST, through March 30, 2011 until 11:59 pm EST.  Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 368488. An archived webcast of the conference call also will be available on the Access Pharma website at www.accesspharma.com.

About Access:Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 Quantum ... scaling volume production of photoactive quantum dots for ... . While offering numerous advantages for solar power ... large quantities of quantum dots with which to ... kept them from commercial utilization and acceptance. The ...
(Date:10/1/2014)... Calif. , Oct. 1, 2014 /PRNewswire/ ... ), a clinical-stage biopharmaceutical company focused on ... positive results from its 371 patient Phase ... with constipation-predominant irritable bowel syndrome (IBS-C).  Results ... clinically meaningful improvement in IBS-C symptoms for ...
(Date:10/1/2014)... LAUSANNE , Switzerland , October ... European leader in Clinical Genomics and Next Generation Sequencing ... Solution allowing clinicians to run full cystic fibrosis analysis ... covers the identification and characterisation of all types of ... analytical performance. Until now, it has not ...
Breaking Medicine Technology:Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
... , BROOKFIELD, Wis. , ... human resources and recruitment outsourcing company, today announced the addition ... Kaiser Permanente Mid-Atlantic States Region, to its Healthcare Advisory Board. ... during this time of monumental change in the healthcare industry. ...
... , MELVILLE, N.Y. , Jan. 25 ... HSIC ), the largest distributor of health care products and services ... of Bradley T. Sheares , Ph.D. to the Company,s Board ... Sheares brings a wealth of health care experience to the Henry ...
Cached Medicine Technology:Pinstripe Welcomes Carrie Harris-Muller To Board 2Pinstripe Welcomes Carrie Harris-Muller To Board 3Pinstripe Welcomes Carrie Harris-Muller To Board 4Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 2Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 3Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 4Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 5
(Date:10/1/2014)... Fredericton, NB (PRWEB) October 01, 2014 Indosoft, ... software Q-Suite, announces that it has added support ... Both Sangoma and Indosoft have a history ... industry. Sangoma's patent-pending technology offers a significant benefit to ... with AMD that is now available to users of Q-Suite. ...
(Date:10/1/2014)... MI (PRWEB) October 01, 2014 To help ... wellness center , Cutler Integrative Medicine, is detailing several tips ... , According to Dr. Cutler, women should start ... quality time for yourself that will help ‘center’ yourself for ... of stress,” he says. , Other health and fitness ...
(Date:9/30/2014)... at the same time could stop them from becoming ... Cancer Research * today (Wednesday). , ... funded by MedImmune, the global biologics research and development ... combining the two treatments helped the immune system hunt ... the initial radiotherapy in mice with breast, skin and ...
(Date:9/30/2014)... News) -- There,s no genetic evidence that high levels ... new study says. Some previous research had suggested ... against type 2 diabetes, raising the possibility of a ... disease. In this study, British researchers investigated the ... on genes that control blood levels of vitamin D. ...
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. 30, 2014 ... put the brakes on motherhood. And for many young women, ... new research suggests. Women in their early 20s appear ... tough economic times. But, according to the new study, that ... 40s and beyond. The findings suggest that higher unemployment ...
Breaking Medicine News(10 mins):Health News:Indosoft Announces Q-Suite Support For Sangoma Lyra 2Health News:In Recognition of National Women’s Health and Fitness Day, Cutler Integrative Medicine Details Tips for Living a Healthier and Happier Life 2Health News:Immunotherapy could stop resistance to radiotherapy 2Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 3
... criticized Advanced Cells Therapeutics, which provided stem cell therapy for ... better than conventional treatments and her illness has not improved. ... Bryson said, "I'm back to where I was before the ... hope it was going to work and it didn't. I ...
... Australians live longer but with more disabilities among the aged. While ... in 1988, more people are suffering disabilities later in life, according ... ,Life expectancy for non-Indigenous Australian men has increased by ... 2003 can expect to live up to 77 and women up ...
... of Punjab and Haryana - will soon have 20 condom ... ,The machines will be installed by the state AIDS ... operate, insure and refill these machines, an official spokesman said. ... men's toilets at various places. ,The points identified ...
... may result from the body overshooting as it tries ... suggests new research// from the University of Massachusetts Amherst ... to a different time zone, the researchers recommend advancing ... allowing the body’s clocks to remain coordinated. The work ...
... results of a Canadian study, a multivitamin pill should ... to reduce risks of having a child with birth ... possibility of a wide range of severe birth defects ... hydrocephalus, heart malformations, truncated or missing limbs, urinary-tract abnormalities ...
... have a deleterious effect on young, developing brains, according ... toddlers is linked to lower IQ scores later in ... problems like diabetes, high cholesterol and hypertension is a ... professor of pediatric genetics at the University of Florida ...
Cached Medicine News:Health News:Model of Internal Clocks Reveals How Jet Lag Disrupts the System 2Health News:Model of Internal Clocks Reveals How Jet Lag Disrupts the System 3Health News:Prenatal multivitamins reduce birth defects 2Health News:Prenatal multivitamins reduce birth defects 3Health News:IQ of Toddlers Affected by Excess weight 2
... The pause of a heartbeat. The ... of rhythmic breathing. These vital signs are ... check. DeRoyals line of Temperature Monitoring products ... the information needed to provide the most ...
... pause of a heartbeat. The bodys warmth ... breathing. These vital signs are yours to ... line of Temperature Monitoring products helps you ... needed to provide the most comfortable and ...
... is a portable, compact, lightweight system with ... emitting the same intensity (50 mW/cm) of ... smaller treatment area (30 cm). Excilite- possesses ... satisfy the most demanding professional users. The ...
... Smart 1064 is a laser system with ... versions with maximum continuous intensities of either 60 ... valid ally in all-mini-invasive surgical techniques. This laser ... it is the most requested from hospitals and ...
Medicine Products: